Tim Smith

These results may support clinical decision-making for psoriasis and nail psoriasis management and may allow future real-world studies to further understand the nature of this skin disease.

The treatment, made up of clindamycin phosphate, adapalene, and benzoyl peroxide, led to clear or almost clear skin among a significant number of individuals with acne.

In this interview segment, Rigotti discussed the way in which cytisinicline can help adults to quit e-cigarettes and the future of her team’s research on this product.

This discussion covered the topic of e-cigarette use and its potential treatment with cytisinicline, a plant-based medication which may aid vapers in quitting.

The tool’s development for scoring severity among complex nail psoriasis cases and monitoring response to treatment may allow for improved outcomes among patients.

These data suggest that a multidisciplinary clinic approach results in several benefits including reduced risk of cardiovascular events among those with psoriasis.

This analysis was designed to look into the timing and specific elements which mediate the relationship between eczema and systemic antibiotic use.

These data highlight the safety, efficacy, and long-term disease control results of treatment with topical ruxolitinib for a subpopulation of adolescents with atopic dermatitis.

These data from investigators at Trinity College Dublin highlighted the immune response mechanisms visible in children with atopic dermatitis.

This analysis covered the different types of attitudes as well as behaviors related to sun exposure and skin cancer risk in Japan, comparing it to individuals in Europe and North America.

These data highlight the elements known to impact patient-reported outcomes among those with psoriasis and successful clinician-reported outcomes following biologic use.

During this interview segment, Browning highlighted the impact of a future FDA acceptance of tapinarof for atopic dermatitis as well as the next milestones in regulatory approval.

In this Lungcast episode segment, Balmes spoke about advocating for air pollution improvements, inequities in air quality, and more.

In this interview, Browning discusses his team’s trial data and the implications of the FDA’s decision to accept the supplemental new drug application for tapinarof as an eczema treatment.

These data shed light on several important findings related to perceptions of hair loss severity among specific groups with central centrifugal cicatricial alopecia and their QoL measures.

This analysis indicates that quantitative interstitial abnormalities may indicate alterations in lung tissue processes that can result in short- and long-term consequences as far as symptoms.

These survey results indicate that young adults tended to embrace misconceptions regarding sun protection and positive views of tanning.

These data suggest vaping poses potential threats to the development of the brain and organs, with teenagers being a predominant target due to surges in use.

In this review of April 2024, the editorial team highlighted some of the biggest stories in the pulmonary health space, touching on topics such as air quality issues, asthma, and pneumonia.

In this review of dermatology news in April, we highlighted several major stories on such topics as cutaneous reactions to COVID-19, topical versus oral minoxidil, and FDA news.

This interview with Bunick featured a discussion of his team’s recent data comparing anti-IL-23 biologics, epitopes, and comparisons with risankizumab.

The decision by Eli Lilly to resubmit lebrikizumab to the FDA for adults and adolescents with eczema is expected to receive a response in the second half of the year.

This segment of the latest Lungcast episode featured a discussion over the ALA’s State of the Air Report and the impacts of particle pollution.

These data allow for a basis for additional research and possible interventions to address psoriasis patients’ demodicosis risk.

The announcement by Dermavant followed positive findings from the ADORING trials on tapinarof and an open label extension for children aged 2 - 17.

This observational cohort study looked at the link between obesity and eczema, highlighting regional differences in the skin disease and obesity’s interdependence.

During this discussion, Ohuabunwa discussed additional takeaways from her ACP conference talk on postdischarge care and other tips for internal medicine physicians.

This discussion with Ohuabunwa was held at the ACP conference and covered inpatient geriatrics assessment tips for internal medicine physicians.

This analysis highlighted several trends in search volume regarding eczema, including correlations with weather and climate.

New phase 3b/4 trial data compared both drugs efficacy and safety profiles for eczema patients, looking at adults and adolescents.